Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.003
Sell
RSI(14)
54.705
Neutral
STOCH(KDJ)(9,3,3)
77.686
Buy
ATR(14)
0.258
High Vlolatility
CCI(14)
68.873
Neutral
Williams %R
6.429
Overbought
TRIX(12,20)
-1.575
Sell
StochRSI(14)
100.000
Buy
X T L Biopharmaceuticals Ltd
XTLBView Detailed Chart
1.215USD
-0.095-7.25%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
10.71MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.25%
5 Days
+7.52%
1 Month
+3.85%
6 Months
-32.87%
Year to Date
-40.02%
1 Year
-54.15%
View Detailed Chart
Agency Rating
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Neutral
Moving Average
Indicators
Value
Direction
MA5
0.742
Buy
MA10
0.944
Buy
MA20
1.068
Buy
MA50
1.250
Sell
MA100
1.523
Sell
MA200
1.945
Sell
News
More news coming soon, stay tuned...
Company
XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Company codeXTLB
CompanyX T L Biopharmaceuticals Ltd
CEOMr. Noam Band
Websitehttps://www.xtlbio.com/
